Overview

Feasibility and Tolerance of Nivolumab Neoadjuvant Immunotherapy in High Risk HPV Driven Oropharynx Cancer

Status:
Recruiting
Trial end date:
2025-05-01
Target enrollment:
Participant gender:
Summary
The aim of this research is to study the feasibility of neoadjuvant treatment before chemoradiation in "high risk" HPV-driven Oropharynx cancer
Phase:
Phase 2
Details
Lead Sponsor:
UNICANCER
Treatments:
Antibodies, Monoclonal
Cisplatin
Nivolumab